Merck's evobrutinib meets in Phase IIb for MS

Merck KGaA (Xetra:MRK) said evobrutinib (M2951, MSC2364447C) met the primary endpoints of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12, 16, 20 and 24 vs. placebo in a Phase IIb trial to treat relapsing multiple sclerosis. The company could not be reached for details or next steps...